Alebund Pharmaceuticals Raises $60 million in Series B Financing Round to Accelerate Its Development of Innovative Drugs and Total Solutions for the Treatment of Renal Diseases
Alebund Pharmaceuticals Raises $60 million in Series B Financing Round to Accelerate Its Development of Innovative Drugs and Total Solutions for the Treatment of Renal Diseases News provided by Share this article Share this article SHANGHAI, May 9, 2021 /PRNewswire/ -- Alebund Pharmaceuticals ("Alebund" or the "Company"), a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions, today announced that it has raised $60 million in its Series B financing round which was led by Quan Capital, and followed by a promin...
Source: prnewswire.com